Institutional Repository UDD

Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis

Show simple item record

dc.contributor.author Cano, Francisco
dc.contributor.author Alarcón, Claudia
dc.contributor.author Azocar, Marta
dc.contributor.author Lizama, Carolina
dc.contributor.author Lillo, Ana María
dc.contributor.author Delucchi, Ángela
dc.contributor.author González, Mariluz
dc.contributor.author Arellano, Patricia
dc.contributor.author Delgado, Iris
dc.contributor.author Droguett, María Teresa
dc.date.accessioned 2016-12-12T23:44:41Z
dc.date.available 2016-12-12T23:44:41Z
dc.date.issued 2011
dc.identifier.citation Pediatric Nephrology, 2011, vol. 26, n° 8, p. 1303-1310
dc.identifier.uri http://hdl.handle.net/11447/886
dc.identifier.uri http://dx.doi.org/10.1007/s00467-011-1846-5
dc.description.abstract The short half-life of erythropoietin (rHuEPO) leads to repeated fluctuations in hemoglobin levels and the need for frequent administration. Continuous erythropoietin receptor activator (CERA) therapy has been approved for once or twice a month in adult dialysis patients. To evaluate the efficacy and safety of CERA therapy in the management of anemia in pediatric peritoneal dialysis (PD) stable PD children under twice-a-week EPO were converted to a subcutaneous CERA, scheduled every 2 weeks. The follow-up was 6 months. The primary efficacy parameter was hemoglobin > 11 g/dL. The exclusion criteria were ferritin < 100 ng/ml and Hb saturation < 20%. Sixteen children, aged 9.75 +/- 3.6 years, including 11 boys, participated in the study. Mean Hb level at month 0 was 10.8 +/- 1.9 g/dL. A decrease in hemoglobin to 10.38 +/- 1 g/dL at month 2 was observed. The CERA dose was increased from 0.86 +/- 0.33 to 1.67 +/- 0.4 mu g/kg at month 3. The target Hb level was reached by the 3rd month. The Hb level and CERA dose were 12.2 +/- 1.2 and 1.6 +/- 0.67 mu g/kg respectively at the end of the study. No adverse events were observed during the protocol. CERA is an effective and safe therapy for maintaining hemoglobin levels when administered twice, up to once a month, in PD children. Doses required to reach target Hb were higher than published experiences in adult populations.
dc.language.iso en_US
dc.subject Erythropoietin
dc.subject EPO
dc.subject CERA
dc.subject Anemia
dc.subject Children
dc.subject Peritoneal dialysis
dc.title Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis
dc.type Artículo


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account